Ann: Trading Halt, page-51

Was never a inquisition or permission it was a simple question. When I read you first 3 posts it was as if they were inviting pumpers to come and play again hence the questions. Didn't require proof etc but old name shows you are knowledgable and logocal. As always knowledge and common sense hopefully saves us from the major frauds and helps keep us holders in the opportunity stocks. Anything that changes teh odds an davoids teh dogs is a positive
Having seen , like you did previously , RHT forum decimated by day trading pumpers and knobs sprouting bullcrap years ago I didn't want to waste my time if that was what was on the books again.
Glad to see you back

In regards to announcement CRO is a big company business so posts regarding growth of CRO market don't apply in a straight line method to possible growth for RHT. Scale and the ecconomy of scale is everything IMO in regards to knowledge and staff required to be a larger CRO and have large margins . That said - niche CRO for a specific speciality like imaging and AI processing which RHT have proven to be good at is offering others would nornmally contract out to RHT or consultants as it has specific knowledge in house. RHT are hardly going to comment on margin or overheads directly so some background knowledge is important looking at their prevous business of acting as CRO . This deal has scale so hopefully the trial is a good one and continues full term to readout so scale of the deal is realised . Up to the numbers hitting the books or some guidance otherwise a punt on trust in managemnt that they have enough margin and skill. So many variables in CRO contracts and also structures of payment. You can in other trials sometimes work out the approx CRO margin by teh upfront as you have a long history of deals but just don't have data with RHT and is in such a specialist area. Is it based on a hourly rate,flat rate include protocol changes etc etc
Due to the specialist nature of RHT knowledge and fact they have FDA approval for own products in this field so have access to prior consultants and some in house retained knowledge they would be 1st choice for further similar trials in Australia especially with low AUD.

I have made assumptions and unless management supply more detail then will ahve to see numbers on accounts to justify change in pricing. Being a CRO is not without risk and hopefully the months gaining this has not distracted them from core business. RHT chasing CRO business may also indicate they have excess fixed resources internally to utilise more fully or to justify listing costs need to turnover more as scan business isn't growing to scale quick enough with such long lead times. New competitiors AI in other fields may also be able to create part of RHT historical database in proof for FDA approval so RHT need to continue to add vale as competition / technology in creating FDA acceptable data will catch up.